Thomson Reuters launches two intelligence software solutions
The Intellectual Property & Science business of Thomson Reuters has launched two new clinical trial intelligence software solutions: Cortellis Clinical Trials Intelligence and Cortellis Site Performance Advisor.
The two are designed to optimize clinical trials, decrease time to market, accelerate clinical trial development and maximize portfolio strategies for professionals in clinical operations and development, R&D benchmarking, R&D strategy, strategic resourcing, precision and translational medicine and at CROs.
Clinical Trials Intelligence allow users to access and search information on more than 130,000 U.S. and global trials for biologics, diagnostics, biomarkers, medical devices and drugs targeting rare diseases, 200,000 press releases, 220,000 literature articles, 2.25 million drug development articles, 21,000 meeting abstracts, 8,000 conference reports and transcripts of analyst and investor meetings. It is available via the web portal or an application programming interface (API).
Clinical Trials Intelligence provides over a dozen visualizations that support fact-based decision making and enhance competitive positioning. It also includes a trial timeline viewer that provides an up-to-date, longitudinal view of the trial start dates, insights on trial duration trends and expected, actual or projected end dates for a given indication, company or individual drug.
Site Performance Advisor is an integrated solution comprising recruiting sites, ideal countries for recruitment and countries that have applicable, relevant patient populations, all critical information for pharmaceutical and CRO executives.